Onkure Therapeutics Inc (OKUR)

Jun 13, 2026

OKUR Q1 2026 Earnings: EPS Miss by 46.55% Signals Aggressive Pipeline InvestmentEarnings Revision Upgrade - newsline.com

Jun 13, 2026

Jun 10, 2026

OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 10, 2026

Jun 08, 2026

OnKure Therapeutics (OKUR) director receives 7,650 stock options grant - Stock Titan

Jun 08, 2026

Jun 08, 2026

OnKure Therapeutics (OKUR) director awarded 1,275 stock options at $4.30 strike - Stock Titan

Jun 08, 2026

Jun 08, 2026

Director at OnKure (NASDAQ: OKUR) receives 7,650 stock options - Stock Titan

Jun 08, 2026

Jun 08, 2026

OnKure (OKUR) awards director 7,650 stock options at $4.30 - Stock Titan

Jun 08, 2026

Jun 08, 2026

OnKure (OKUR) director receives 7,650 options at $4.30 strike - Stock Titan

Jun 08, 2026

Jun 08, 2026

OnKure (OKUR) director awarded 7,650 stock options at $4.30 strike - Stock Titan

Jun 08, 2026

Jun 08, 2026

Onkure Therapeutics patents new PI3Kα mutant inhibitors - BioWorld News

Jun 08, 2026

Jun 07, 2026

OKUR Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue StageSlow Growth Warning - newsline.com

Jun 07, 2026

Jun 05, 2026

OnKure Shareholders Approve Amended 2024 Equity Incentive Plan - The Globe and Mail

Jun 05, 2026

Jun 04, 2026

OnKure (NASDAQ: OKUR) holders back equity plan changes and board slate - Stock Titan

Jun 04, 2026

Jun 02, 2026

OnKure Therapeutics (OKUR) Holds Steady Near Support: Can $4.43 Resistance Be Breached?Breakout Confirmation - newsline.com

Jun 02, 2026

Jun 01, 2026

OKUR Q1 2026 Earnings: EPS Miss of 46.6% Highlights Early-Stage R&D CostsGuidance Upgrade Report - thelegaladvocate.com

Jun 01, 2026

May 29, 2026

OnKure Therapeutics (OKUR) Advances 2.55% as Stock Holds Above Key SupportBollinger Expansion - The Legal Advocate

May 29, 2026

May 28, 2026

OKUR Q1 2026 Earnings: Wider EPS Loss Underscores Heavy R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Surprise Stocks - newsline.com

May 28, 2026

May 27, 2026

[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan

May 27, 2026

May 27, 2026

OKUR Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEarnings Stability Report - The Legal Advocate

May 27, 2026

May 26, 2026

OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineMargin Guidance - The Legal Advocate

May 26, 2026

May 22, 2026

Survey finds most Boulder residents satisfied with quality of life - BizWest

May 22, 2026

May 21, 2026

OnKure Therapeutics (OKUR) Surges 14% Amid Renewed Investor InterestMerger Arbitrage - Newser

May 21, 2026

May 21, 2026

OnKure Therapeutics (OKUR) Q1 2026 Earnings Miss: EPS $-1.11 vs $-0.76 ExpectedReal Trader Insights - Newser

May 21, 2026

May 20, 2026

OnKure Therapeutics (OKUR) Jumps +7.88% on Strong Momentum 2026-05-20Technical Analysis Picks - The Legal Advocate

May 20, 2026

May 15, 2026

ADAR1 entities and Daniel Schneeberger report 6.0% of OnKure (NASDAQ: OKUR) - Stock Titan

May 15, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 11, 2026

The long term thesis for OnKure Therapeutics (OKUR) in plain sight (Breakdown Watch) 2026-05-11Social Momentum Signals - newser.com

May 11, 2026

May 10, 2026

OnKure Therapeutics (OKUR) Receives a Rating Update from a Top Analyst - The Globe and Mail

May 10, 2026

May 07, 2026

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail

May 07, 2026

May 07, 2026

OnKure Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks

May 07, 2026

May 06, 2026

OnKure Therapeutics war chest nears $200M following spring stock sale - BizWest

May 06, 2026

May 06, 2026

OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target - TipRanks

May 06, 2026

May 06, 2026

Oppenheimer Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $30 - Moomoo

May 06, 2026

May 05, 2026

Onkure Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 05, 2026

May 05, 2026

[10-Q] OnKure Therapeutics, Inc. Quarterly Earnings Report - Stock Titan

May 05, 2026

May 05, 2026

OnKure (Nasdaq: OKUR) lifts cash to $192.1 million after raise - Stock Titan

May 05, 2026

May 05, 2026

OnKure bets on 2 PI3K drugs for breast cancer and vascular anomalies - Stock Titan

May 05, 2026

May 05, 2026

OnKure Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 05, 2026

May 05, 2026

OnKure Therapeutics Reports First Quarter 2026 Financial Results - marketscreener.com

May 05, 2026

May 05, 2026

[EFFECT] OnKure Therapeutics, Inc. SEC Filing - Stock Titan

May 05, 2026

May 01, 2026

Aclarion reports cash runway to ops into late 2027 - BizWest

May 01, 2026

Apr 30, 2026

What date does OnKure Therapeutics, Inc.'s (OKUR) report EarningsEarnings Calendar & Announcement - Zacks Investment Research

Apr 30, 2026

Apr 28, 2026

OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60 - MSN

Apr 28, 2026

Apr 28, 2026

OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Apr 28, 2026

Apr 27, 2026

OnKure Therapeutics prices $150M oversubscribed private placement - MSN

Apr 27, 2026

Apr 27, 2026

What top holdings OnKure Therapeutics (OKUR)? (Smart Money Active) 2026-04-27Earnings Beat Stocks - Newser

Apr 27, 2026

Apr 27, 2026

OKUR (OnKure Therapeutics) reports narrower Q4 2025 loss than estimates, shares drop 2.04 percent in trading.Revenue Growth Rate - Newser

Apr 27, 2026

Apr 26, 2026

Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Drops By 57.6% - MarketBeat

Apr 26, 2026